Suchergebnisse - "Touzeau, Cyrille"

PubPharm (16)

1

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

enthalten in: The New England journal of medicine | 2023

von San-Miguel, J. | Dhakal, B. | Yong, K. | +40

2

All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients : final results of the phase II IFM 2013-06 study

enthalten in: Haematologica | 2022

von Touzeau, C. | Perrot, A. | Roussel, M. | +15

3

Elotuzumab : no benefit for older patients with newly diagnosed multiple myeloma

enthalten in: The Lancet. Haematology | 2022

von Touzeau, C.

CommentOn: Lancet Haematol. 2022 Jun;9(6):e403-e414. - PMID 35550060

4

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma : frailty subgroup analysis of MAIA

enthalten in: Leukemia | 2022

von Facon, T. | Cook, G. | Usmani, S. | +25

5

Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021

von Richardson, P. | Kumar, S. | Masszi, T. | +19

CommentIn: J Clin Oncol. 2021 Aug 1;39(22):2423-2425. - PMID 34111942

6

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma : the IFM KRd final results

enthalten in: Blood | 2021

von Roussel, M. | Lauwers-Cances, V. | Wuilleme, S. | +16

CommentIn: Blood. 2021 Jul 15;138(2):105-106. - PMID 34264276

7

Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES) : an open-label Phase II study

enthalten in: British journal of haematology | 2021

von Chari, A. | Rodriguez-Otero, P. | McCarthy, H. | +18

8

Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma

enthalten in: Future oncology (London, England) | 2021

von Touzeau, C. | Antier, C. | Moreau, P.

9

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting : a single-center retrospective study

enthalten in: Annals of hematology | 2019

von Trudel, S. | Tessoulin, B. | Jullien, M. | +14

10

Ixazomib in the management of relapsed multiple myeloma

enthalten in: Future oncology (London, England) | 2018

von Touzeau, C. | Moreau, P.